As FDA door shuts on its PI3K, MEI Pharma throws in the towel, lays off staff

Having steered a PI3K inhibitor from preclinical studies all the way to Phase II, San Diego’s MEI Pharma is all but washing its hands of the drug as the FDA raises the bar on the class. The biotech is discontinuing development of zandelisib everywhere except Japan, where its partner Kyowa…

Click here to view original post